Erratum: Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer (Angiogenesis (2010) 13 (43-58) DOI: 10.1007/s10456-010-9163-3);Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer

Angiogenesis

Volumn 13, Issue 1, 2010, Pages 43-58

  Carpini, Jennifer Delli ^a   Karam, Amer K ^a   Montgomery, Leslie ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer; Cervical cancer; Mitogen; Ovarian cancer; Vascular endothelial growth factor; VEGF

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; NAVELBINE; PACLITAXEL; SEX HORMONE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CORPUS LUTEUM; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; HUMAN; MULTIPLE CYCLE TREATMENT; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UPREGULATION; UTERINE CERVIX CANCER;

HUMAN PAPILLOMAVIRUS;

EID: 77950690217     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-010-9171-3     Document Type: Erratum

References (105)

1. Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77(7):527-543 (Pubitemid 29426311)
2. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219(4587):983-985
3. Folkman J, Merler E, Abernathy C, Williams G (1971) Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133(2):275-288
4. Schoppmann SF, Horvat R, Birner P (2002) Lymphatic vessels and lymphangiogenesis in female cancer: mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies (Review). Oncol Rep 9(3):455-460
5. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, Isselbacher KJ (eds) (2005) Cancer cell biology and angiogenesis: introduction, 16th edn. McGraw-Hill, New York Harrison's Principles of Internal Medicine; No.5
6. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18(1):4-25 (Pubitemid 27076453)
7. Dvorak HF (1986) Tumors: wounds that do not heal. N Engl J Med 315(26):1650-1659
8. Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM (1987) Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 57(6):673-686 (Pubitemid 18031786)
9. Vincenti V, Cassano C, Rocchi M, Persico G (1996) Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93(8):1493-1495 (Pubitemid 26115412)
10. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266(18):11947-11954 (Pubitemid 21907041)
11. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5(12):1806-1814
12. Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, Ferrara N (1996) The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 271(13):7788-7795 (Pubitemid 26111064)
13. Jakeman LB, Winer J, Bennett GL, Altar CA, Ferrara N (1992) Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 89(1): 244-253
14. Jakeman LB, Armanini M, Phillips HS, Ferrara N (1993) Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology 133(2):848-859 (Pubitemid 23238902)
15. Vaisman N, Gospodarowicz D, Neufeld G (1990) Characterization of the receptors for vascular endothelial growth factor. J Biol Chem 265(32):19461-19466 (Pubitemid 120013886)
16. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM, Feder J (1989) Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84(5):1470-1478 (Pubitemid 19272234)
17. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255(5047): 989-991
18. Cunningham SA, Waxham MN, Arrate PM, Brock TA (1995) Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. Mapping of a novel site involved in binding. J Biol Chem 270(35):20254-20257
19. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269(43):26988-26995 (Pubitemid 24332901)
20. Guo D, Jia Q, Song HY, Warren RS, Donner DB (1995) Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 270(12):6729-6733
21. Kendall RL, Wang G, Thomas KA (1996) Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226(2):324-328 (Pubitemid 26331903)
22. Toi M, Kondo S, Suzuki H, Yamamoto Y, Inada K, Imazawa T, Taniguchi T, Tominaga T (1996) Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 77(6):1101-1106 (Pubitemid 26080900)
23. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57(20):4593-4599 (Pubitemid 27441066)
24. Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A, Mori T, Yoshida M, Ikeda T, Tominaga T (1996) Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 2(5):821-826 (Pubitemid 26168934)
25. Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ, Cairnduff F, Selby PJ, Perren TJ, Lansdown M, Banks RE (2000) Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 60(11):2898-2905 (Pubitemid 30395813)
26. Veronesi U, Galimberti V, Zurrida S, Merson M, Greco M, Luini A (1993) Prognostic significance of number and level of axillary nodal metastases in breast cancer. Breast 2:224-228 (Pubitemid 24003491)
27. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124(7): 966-978 (Pubitemid 30602038)
28. Toi M, Kashitani J, Tominaga T (1993) Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55(3):371-374 (Pubitemid 23300581)
29. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in earlystage breast carcinoma. J Natl Cancer Inst 84(24):1875-1887 (Pubitemid 23004615)
30. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL (1992) Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340(8828):1120-1124
31. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O, Barbareschi M, Boracchi P, Marubini E, Pozza F (1994) Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12(3):454-466 (Pubitemid 24079885)
32. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57(5):963-969 (Pubitemid 27098025)
33. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP (1996) Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 56(9):2013-2016 (Pubitemid 26119899)
34. Guidi AJ, Berry DA, Broadwater G, Perloff M, Norton L, Barcos MP, Hayes DF (2000) Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst 92(6):486-492 (Pubitemid 30182886)
35. Osanai T, Wakita T, Gomi N, Takenaka S, Kakimoto M, Sugihara K (2003) Correlation among intratumoral blood flow in breast cancer, clinicopathological findings and Nottingham Prognostic Index. Jpn J Clin Oncol 33(1):14-16 (Pubitemid 43102874)
36. Linderholm B, Tavelin B, Grankvist K, Henriksson R (1998) Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16(9):3121-3128 (Pubitemid 28417435)
37. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T (1997) Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89(2):139-147 (Pubitemid 27034790)
38. Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R (2000) Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 18(7):1423-1431 (Pubitemid 30205387)
39. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijervan Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CG, Klijn JG (2001) High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61(14):5407-5414 (Pubitemid 32694919)
40. Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes J.M., Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD (2004) Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10(5):1706-1716 (Pubitemid 38435562)
41. Kawai H, Li H, Chun P, Avraham S, Avraham HK (2002) Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene 21(50):7730-7739 (Pubitemid 35398818)
42. Bausero P, Ben-Mahdi M, Mazucatelli J, Bloy C, Perrot-Applanat M (2000) Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia. Am J Physiol Heart Circ Physiol 279(5):H2033-H2042
43. Ali SH, O'Donnell AL, Balu D, Pohl MB, Seyler MJ, Mohamed S, Mousa S, Dandona P (2000) Estrogen receptor-alpha in the inhibition of cancer growth and angiogenesis. Cancer Res 60(24):7094-7098 (Pubitemid 32059189)
44. Hartman J, Lindberg K, Morani A, Inzunza J, Strom A, Gustafsson JA (2006) Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 66(23):11207-11213 (Pubitemid 46009948)
45. Johns A, Freay AD, Fraser W, Korach KS, Rubanyi GM (1996) Disruption of estrogen receptor gene prevents 17 beta estradiol-induced angiogenesis in transgenic mice. Endocrinology 137(10):4511-4513 (Pubitemid 26321904)
46. Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J, Perrot-Applanat M (2002) Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Cancer Res 62(17):4977-4984 (Pubitemid 34984422)
47. Fuckar D, Dekanic A, Stifter S, Mustac E, Krstulja M, Dobrila F, Jonjic N (2006) VEGF expression is associated with negative estrogen receptor status in patients with breast cancer. Int J Surg Pathol 14(1):49-55 (Pubitemid 43221616)
48. Heer K, Kumar H, Read JR, Fox JN, Monson JR, Kerin MJ (2001) Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin Cancer Res 7(11):3491-3494 (Pubitemid 33069985)
49. Bando H (2007) Vascular endothelial growth factor and bevacitumab in breast cancer. Breast Cancer 14(2):163-173
50. Bahri S, Chen JH, Mehta RS, Carpenter PM, Nie K, Kwon SY, Yu HJ, Nalcioglu O, Su MY (2009) Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without Bevacizumab. Ann Surg Oncol
51. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J, Doshi A, Thomasson D, McCarthy N, Koeppen H, Sherman M, Zujewski J, Camphausen K, Chen H, Swain SM (2006) Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24(5):769-777 (Pubitemid 46622044)
52. Balduzzi A, Montagna E, Bagnardi V, Torrisi R, Bertolini F, Mancuso P, Scarano E, Viale G, Veronesi P, Cardillo A, Orlando L, Goldhirsch A, Colleoni M (2009) Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. Anticancer Drugs
53. Greil R, Moik M, Reitsamer R, Ressler S, Stoll M, Namberger K, Menzel C, Mlineritsch B (2009) Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neunegative invasive breast cancer: efficacy and safety in a phase II pilot study. Eur J Surg Oncol
54. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A (2003) A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30(5 Suppl 16):117-124 (Pubitemid 37433402)
55. Ramaswamy B, Elias AD, Kelbick NT, Dodley A, Morrow M, Hauger M, Allen J, Rhoades C, Kendra K, Chen HX, Eckhardt SG, Shapiro CL (2006) Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 12(10):3124-3129 (Pubitemid 43837360)
56. Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP (2008) VEGF as a marker for outcome among advanced breast cancer patients receiving anti- VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 14(23):7871-7877
57. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666-2676
58. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23(4):792-799 (Pubitemid 46224178)
59. Traina TA, Rugo HS, Dickler M (2007) Bevacizumab for advanced breast cancer. Hematol Oncol Clin North Am 21(2):303-319 (Pubitemid 46754733)
60. Torry DS, Holt VJ, Keenan JA, Harris G, Caudle MR, Torry RJ (1996) Vascular endothelial growth factor expression in cycling human endometrium. Fertil Steril 66(1):72-80 (Pubitemid 26190024)
61. Bausero P, Cavaille F, Meduri G, Freitas S, Perrot-Applanat M (1998) Paracrine action of vascular endothelial growth factor in the human endometrium: production and target sites, and hormonal regulation. Angiogenesis 2(2):167-182 (Pubitemid 128511984)
62. Bassett DEL (1943) The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle. Am J Anat 73:251-278
63. Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, Chisholm V, Hillan KJ, Schwall RH (1998) Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4(3):336-340 (Pubitemid 28144094)
64. Kamat BR, Brown LF, Manseau EJ, Senger DR, Dvorak HF (1995) Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am J Pathol 146(1):157-165
65. Gordon JD, Mesiano S, Zaloudek CJ, Jaffe RB (1996) Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. J Clin Endocrinol Metab 81(1):353-359 (Pubitemid 26035045)
66. Heer K, Kumar H, Speirs V, Greenman J, Drew PJ, Fox JN, Carleton PJ, Monson JR, Kerin MJ (1998) Vascular endothelial growth factor in premenopausal women-indicator of the best time for breast cancer surgery? Br J Cancer 78(9):1203-1207 (Pubitemid 28479152)
67. Agrawal R, Conway GS, Sladkevicius P, Payne NN, Bekir J, Campbell S, Tan SL, Jacobs HS (1999) Serum vascular endothelial growth factor (VEGF) in the normal menstrual cycle: association with changes in ovarian and uterine Doppler blood flow. Clin Endocrinol (Oxf) 50(1):101-106 (Pubitemid 29079374)
68. Chung HC, Rha SY, Ahn JB, Shim KY, Yoo NC, Kim JH, Roh J.K., Lee KS, Min JS, Kim BS, Kim JJ (1998) Menstrual state should be considered in determining sero-positivity of soluble angiogenic factors in breast cancer. Int J Mol Med 2(4):465-470
69. Shweiki D, Itin A, Neufeld G, Gitay-Goren H, Keshet E (1993) Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest 91(5):2235-2243 (Pubitemid 23141500)
70. Cullinan-Bove K, Koos RD (1993) Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology 133(2):829-837 (Pubitemid 23238899)
71. Charnock-Jones DS, Sharkey AM, Rajput-Williams J, Burch D, Schofield JP, Fountain SA, Boocock CA, Smith SK (1993) Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. Biol Reprod 48(5):1120-1128 (Pubitemid 23107814)
72. Perrot-Applanat M, Ancelin M, Buteau-Lozano H, Meduri G, Bausero P (2000) Ovarian steroids in endometrial angiogenesis. Steroids 65(10-11):599-603
73. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57(1):43-66 (Pubitemid 46148091)
74. Olson TA, Mohanraj D, Carson LF, Ramakrishnan S (1994) Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 54(1):276-280 (Pubitemid 24042123)
75. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR, Smith SK (1995) Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87(7):506-516
76. Paley PJ, Goff BA, Gown AM, Greer BE, Sage EH (2000) Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. Gynecol Oncol 78(3 Pt 1):336-341
77. Fujimoto J, Sakaguchi H, Hirose R, Ichigo S, Tamaya T (1998) Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma. Cancer 83(12): 2528-2533 (Pubitemid 29019573)
78. Hazelton D, Nicosia RF, Nicosia SV (1999) Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res 5(4):823-829 (Pubitemid 29180834)
79. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ (1998) Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 90(6):447-454 (Pubitemid 28160636)
80. Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF, Ramakrishnan S (1997) Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80(1):98-106 (Pubitemid 27270925)
81. Hartenbach EM, Olson TA, Goswitz JJ, Mohanraj D, Twiggs LB, Carson LF, Ramakrishnan S (1997) Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 121(2):169-175 (Pubitemid 28008916)
82. Tempfer C, Obermair A, Hefler L, Haeusler G, Gitsch G, Kainz C (1998) Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol 92(3):360-363 (Pubitemid 28396857)
83. Obermair A, Tempfer C, Hefler L, Preyer O, Kaider A, Zeillinger R, Leodolter S, Kainz C (1998) Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. Br J Cancer 77(11): 1870-1874 (Pubitemid 28254626)
84. Cooper BC, Ritchie J.M., Broghammer CL, Coffin J, Sorosky JI, Buller RE, Hendrix MJ, Sood AK (2002) Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res 8(10):3193-3197 (Pubitemid 35155030)
85. Mesiano S, Ferrara N, Jaffe RB (1998) Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153(4):1249-1256 (Pubitemid 28465848)
86. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25(33):5165-5171 (Pubitemid 350237599)
87. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25(33):5180-5186 (Pubitemid 350232248)
88. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26(1):76-82
89. Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, Salgia R, Stadler WM, Vokes EE, Fleming GF (2008) Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.Gynecol Oncol 110(1):49-55
90. Han ES, Lin P, Wakabayashi M (2009) Current status on biologic therapies in the treatment of epithelial ovarian cancer. Curr Treat Options Oncol
91. Han ES, Monk BJ (2007) Bevacizumab in the treatment of ovarian cancer. Expert Rev Anticancer Ther 7(10):1339-1345
92. Bosch FX, de Sanjose S (2003) Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr (31):3-13
93. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55(4):244-265 (Pubitemid 34293391)
94. Smith-McCune KK, Weidner N (1994) Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 54(3):800-804 (Pubitemid 24068340)
95. Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF, Brown LF (1995) Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 87(16):1237-1245
96. Kodama J, Seki N, Tokumo K, Hongo A, Miyagi Y, Yoshinouchi M, Okuda H, Kudo T (1999) Vascular endothelial growth factor is implicated in early invasion in cervical cancer. Eur J Cancer 35(3):485-489 (Pubitemid 29151950)
97. Tokumo K, Kodama J, Seki N, Nakanishi Y, Miyagi Y, Kamimura S, Yoshinouchi M, Okuda H, Kudo T (1998) Different angiogenic pathways in human cervical cancers. Gynecol Oncol 68(1):38-44 (Pubitemid 28109821)
98. Santin AD, Hermonat PL, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP (1999) Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Obstet Gynecol 94(1):78-82 (Pubitemid 29284430)
99. Loncaster JA, Cooper RA, Logue JP, Davidson SE, Hunter RD, West CM (2000) Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 83(5):620-625 (Pubitemid 30636303)
100. Cheng WF, Chen CA, Lee CN, Chen TM, Hsieh FJ, Hsieh CY (1999) Vascular endothelial growth factor in cervical carcinoma. Obstet Gynecol 93(5 Pt 1):761-765 (Pubitemid 29190678)
101. Cheng WF, Chen CA, Lee CN, Wei LH, Hsieh FJ, Hsieh CY (2000) Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstet Gynecol 96(5 Pt 1):721-726
102. Walboomers J.M., Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1):12-19 (Pubitemid 29406813)
103. Smith-McCune K, Zhu YH, Hanahan D, Arbeit J (1997) Crossspecies comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice. Cancer Res 57(7):1294-1300 (Pubitemid 27152554)
104. Lopez-Ocejo O, Viloria-Petit A, Bequet-Romero M, Mukhopadhyay D, Rak J, Kerbel RS (2000) Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 19(40):4611-4620
105. Wright JD, Viviano D, Powell MA, Gibb RK, Mutch DG, Grigsby PW, Rader JS (2006) Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol 103(2):489-493 (Pubitemid 44602157)